Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Recommendation of “Moderate Buy” from Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has received a consensus recommendation of “Moderate Buy” from the eighteen ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $289.8824.

A number of research analysts have recently issued reports on ASND shares. TD Cowen restated a “buy” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, January 7th. Bank of America reiterated a “buy” rating and set a $262.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday, March 5th. Stifel Nicolaus set a $332.00 target price on shares of Ascendis Pharma A/S in a report on Wednesday, March 4th. Wolfe Research restated an “outperform” rating and issued a $260.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Finally, Wells Fargo & Company upped their target price on Ascendis Pharma A/S from $322.00 to $330.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds have recently bought and sold shares of the company. Advisory Services Network LLC bought a new stake in shares of Ascendis Pharma A/S during the third quarter valued at approximately $26,000. Arax Advisory Partners lifted its stake in shares of Ascendis Pharma A/S by 212.2% in the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 104 shares during the period. Leonteq Securities AG acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter valued at approximately $42,000. Finally, Global Retirement Partners LLC raised its holdings in Ascendis Pharma A/S by 111.9% during the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 113 shares in the last quarter.

Ascendis Pharma A/S Trading Down 1.3%

Shares of ASND opened at $225.98 on Tuesday. Ascendis Pharma A/S has a 52 week low of $124.06 and a 52 week high of $248.60. The firm has a market cap of $14.01 billion, a price-to-earnings ratio of -51.36 and a beta of 0.43. The stock has a 50 day moving average of $224.24 and a 200-day moving average of $211.20.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 11th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.58). The company had revenue of $290.38 million during the quarter, compared to analysts’ expectations of $285.35 million. On average, sell-side analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.